The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kelly John Alexander since 2022.
This trader's CIK number is 1590030.
At the time of last reporting, Kelly John Alexander was the Chief Financial Officer of Precision Biosciences Inc. (stock ticker symbol DTIL).
Also see all insider trading activities at Precision Biosciences Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | DTIL | 0 | $0 | 14,827 | $63,163 | 46,070 | $0 |
| 2024 | DTIL | 3,000 | $20,280 | 0 | $0 | 122,451 | $0 |
| 2023 | DTIL | 20,000 | $17,200 | 0 | $0 | 206,985 | $0 |
| 2022 | DTIL | 95,698 | $161,756 | 0 | $0 | 47,728 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-03 | DTIL | Sale | 14,827 | 4.26 | 63,163 |
| 2025-03-03 | DTIL | Option Ex | 1,702 | .00 | 0 |
| 2025-01-20 | DTIL | Option Ex | 44,368 | .00 | 0 |
| 2024-11-21 | DTIL | Buy | 3,000 | 6.76 | 20,280 |
| 2024-11-02 | DTIL | Option Ex | 3,605 | .00 | 0 |
| 2024-06-07 | DTIL | Option Ex | 454 | .00 | 0 |
| 2024-05-01 | DTIL | Option Ex | 1,702 | .00 | 0 |
| 2024-01-20 | DTIL | Option Ex | 116,690 | .00 | 0 |
| 2023-11-02 | DTIL | Option Ex | 108,188 | .00 | 0 |
| 2023-06-07 | DTIL | Option Ex | 47,726 | .00 | 0 |
| 2023-03-17 | DTIL | Buy | 20,000 | .86 | 17,200 |
| 2023-03-03 | DTIL | Option Ex | 51,071 | .00 | 0 |
| 2022-09-22 | DTIL | Buy | 37,037 | 1.34 | 49,629 |
| 2022-09-23 | DTIL | Buy | 8,200 | 1.23 | 10,086 |
| 2022-06-22 | DTIL | Buy | 33,784 | 1.50 | 50,676 |
| 2022-06-07 | DTIL | Option Ex | 47,728 | .00 | 0 |
| 2022-03-17 | DTIL | Buy | 16,677 | 3.08 | 51,365 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kelly John Alexander (Chief Financial Officer of Precision Biosciences Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.